Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12878838rdf:typepubmed:Citationlld:pubmed
pubmed-article:12878838lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:12878838lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:12878838pubmed:issue3lld:pubmed
pubmed-article:12878838pubmed:dateCreated2003-7-24lld:pubmed
pubmed-article:12878838pubmed:abstractTextThe field of tissue engineering, involving the reprogramming of stem cells or rejuvenation of specific differentiated cells, is emerging as a promising strategy to repair the damaged myocardium. The eventual goal is to be able to take a patient's own cells, expand them ex vivo, genetically engineer them to enhance specific properties, and then reintroduce them into the patient's heart to create a replacement tissue. Our review paper describes data that supports the potential of this strategy. This clinically relevant, combined strategy of genetic and tissue engineering could be of importance in treating elderly patients with massive myocardial damage, patients whose normal myogenic or angiogenic cells have been depleted or are inadequate in their growth potential, to prevent LV deterioration and heart failure.lld:pubmed
pubmed-article:12878838pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12878838pubmed:languageenglld:pubmed
pubmed-article:12878838pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12878838pubmed:citationSubsetIMlld:pubmed
pubmed-article:12878838pubmed:statusMEDLINElld:pubmed
pubmed-article:12878838pubmed:monthJullld:pubmed
pubmed-article:12878838pubmed:issn1382-4147lld:pubmed
pubmed-article:12878838pubmed:authorpubmed-author:KlonerRobert...lld:pubmed
pubmed-article:12878838pubmed:authorpubmed-author:LeorJonathanJlld:pubmed
pubmed-article:12878838pubmed:authorpubmed-author:BattlerAlexan...lld:pubmed
pubmed-article:12878838pubmed:authorpubmed-author:EtzionSharonSlld:pubmed
pubmed-article:12878838pubmed:issnTypePrintlld:pubmed
pubmed-article:12878838pubmed:volume8lld:pubmed
pubmed-article:12878838pubmed:ownerNLMlld:pubmed
pubmed-article:12878838pubmed:authorsCompleteYlld:pubmed
pubmed-article:12878838pubmed:pagination285-92lld:pubmed
pubmed-article:12878838pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:meshHeadingpubmed-meshheading:12878838...lld:pubmed
pubmed-article:12878838pubmed:year2003lld:pubmed
pubmed-article:12878838pubmed:articleTitleReprogramming cells for transplantation.lld:pubmed
pubmed-article:12878838pubmed:affiliationNeufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer, Israel. leorj@post.tau.ac.illld:pubmed
pubmed-article:12878838pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12878838pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12878838pubmed:publicationTypeReviewlld:pubmed
pubmed-article:12878838pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed